Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Maintenance in Aggressive B-cell Lymphoma (NHL-13)
NCT00400478Phase 3Completed
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Start
- Jan 2006
- Primary completion
- Mar 2013
- Modality
- Monoclonal Antibodies
- Countries
- 26
01
Overview
A Phase 3 trial of rituximab in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Started Jan 2006; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00400478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00400478.